Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.

Chemotherapy-induced nausea and vomiting can severely impact patients’ quality of life and treatment adherence. In a major ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...